A single-arm, open-label, prospective phase 2 trial of SABR at various sites was carried out by Hannan et al. with the objective to assess if the addition of SABR to high-dose IL2 (HD IL2) could raise the overall response rate along with tissue analyses in oligometastatic RCC with ≤6 lesions. Here, IL2 is linked to renal cell carcinoma.